Výsledky vyhledávání - "Anthony Trombino"

Abstract P02-04: BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases

Autor: Matthew C. Lucas, Melinda S. Merchant, Matthew O'Connor, Carl Cook, Sherri Smith, Anthony Trombino, Wu-Yan Zhang, Irache Visiers, Kate Tith, Reza Foroughi, Nigel Waters, Iwona Wrona, Michael Pickard, Sudharshan Eathiraj, Karsten Witt, Christopher Roberts, Rachel Humphrey, Elizabeth Buck

Publikováno v: Molecular Cancer Therapeutics. 20:P02-04

NSCLC accounts for approximately 85% of lung cancer cases worldwide. NSCLC harboring EGFR mutations constitutes 10-20% of all lung cancer cases in Europe and North America, and up to 50% of those in Asia. The majority (80-90%) of these mutations are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae653c049d0da4a11d8de415f56e2dfa
https://doi.org/10.1158/1535-7163.targ-21-p02-04

Zobrazit plný text záznamu

Abstract 3396: Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM

Autor: Matthew O'Connor, Matthew Lucas, Sherri Smith, Anthony Trombino, Sudharshan Eathiraj, Elizabeth Buck

Publikováno v: Cancer Research. 83:3396-3396

Acquired resistance to 3rd generation EGFR inhibitors used in the treatment of NSCLC is common. While the EGFR C797S substitution is a frequently reported post-osimertinib resistance mutation, real world evidence indicates the emergence of additional

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b2814b5738d82f0f4e874c237321802
https://doi.org/10.1158/1538-7445.am2023-3396

Zobrazit plný text záznamu

Abstract P246: Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers

Autor: Etienne Dardenne, Fernando Padilla, Sara Rasmussen, Shao Ning Yang, Ahmet Mentes, Luisa Shin Ogawa, Anthony Trombino, Darlene Romashko, Maria Chevtsova, Shalabh Thakur, Elisabeth Buck, Christopher Roberts, Matthew Lucas, Tai-An Lin

Publikováno v: Molecular Cancer Therapeutics. 20:P246-P246

Background: Targeting FGFR genetic alterations using small molecule inhibitors is a validated therapeutic strategy for urothelial carcinoma and cholangiocarcinoma. However, the current FDA-approved pan-FGFR inhibitors, erdafitinib and pemigatinib, ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42d8231d07692ff19f317f72f2d34562
https://doi.org/10.1158/1535-7163.targ-21-p246

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání